USPTO Eases Design Patents for Computer Icons and Interfaces
Published Date: 3/13/2026
Notice
Summary
The USPTO just updated its rules to give designers more freedom when applying for patents on computer-generated interfaces and icons. This change affects anyone filing or already working on design patent applications related to digital images, starting March 13, 2026. It means you can now show your cool, original designs in new ways without extra hassle—no extra fees, just more creative control!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
No Display Panel Drawing Required
If you file a design patent for a computer-generated interface or icon, you no longer must show the display screen or part of it in solid or broken lines in the drawings when both the title and the claim properly identify an article of manufacture (for example, a "computer" or a "computer display screen"). This change is effective March 13, 2026 and applies to applications and proceedings filed before, on, or after March 13, 2026.
Claim Language 'For' Is Sufficient
If your title or claim says an icon or interface is "for" a computer, computer display, or computer system (for example, "icon for display panel" or "projected interface for computer"), the USPTO will treat that wording as adequately describing an article of manufacture and examiners will no longer be instructed to object to such claims under 37 CFR 1.153 or 37 CFR 1.1067. This clarification is effective March 13, 2026 and applies to applications and proceedings filed before, on, or after March 13, 2026.
Design Patents May Cover Projections and Holograms
The USPTO says designs for computer-generated interfaces and icons that are separate from the device that generates them—such as projections, holograms, and other virtual or augmented reality (PHVAR) interfaces—can be eligible for design patent protection when properly disclosed and claimed. This update is effective March 13, 2026 and applies to applications and proceedings filed before, on, or after March 13, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
Previous / Next Documents
Previous: 2026-04986, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Federal Student Aid User Experience Design Research Generic Clearance
The Department of Education wants to keep collecting feedback from students and families to make Federal Student Aid easier to use. They’re asking for public comments by April 13, 2026, to make sure this process stays helpful without causing extra hassle. This effort won’t cost more or change how often they ask for info, but it helps improve student aid services for everyone.
Next: 2026-04988, Office of the Secretary; Cancellation of Meeting
The big March 19th meeting for the Interagency Autism Coordinating Committee at NIH is canceled. If you were planning to attend or follow updates, don’t worry—a new date will be announced soon. No money or deadlines are affected right now, so just stay tuned for the next notice!